Impel NeuroPharma Inc. (IMPL) stock plunged at last close, followed by no current update.

Impel NeuroPharma Inc. (NASDAQ: IMPL) stock declined by 0.79% at the last close.  Impel NeuroPharma is a commercial-stage pharmaceutical firm focused on discovering innovative medicines for people suffering from illness with significant unmet medical needs, with a major emphasis on central nervous system ailments.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


IMPL stock’ Past Development

On Nov 15, 2021, Impel announced its financial results for the third quarter of 2021. Given below are the highlights:

  • In the third quarter of 2021, R&D expenses were $5.9 million, compared to $6.1 million in the third quarter of 2020. The drop in R&D investment was mostly due to lower clinical costs for Trudhesa as the Phase 3 study came to an end.
  • SG&A expenses were $16.3 million in the third quarter of 2021, compared to $2.9 million in the third quarter of 2020. The rise in SG&A was primarily attributable to increased spending to support commercial and marketing preparations for the Trudhesa launch.
  • Impel recorded a net loss of $25.0 million in Q3 of 2021, whereas the net loss was $9.2 million in the third quarter of 2020.
  • In the third quarter of 2021, GAAP Net Loss per Share was $1.24 per share, compared to $15.56 in the third quarter of 2020.
  • In the third quarter of 2021, non-GAAP Net Loss per Share was $1.23, compared to $0.49 in the third quarter of 2020.
  • The company had $111.3 million in cash and cash equivalents as of September 30, 2021.

Adrian Adams, Chairman and CEO of Impel NeuroPharma commented that,

The third quarter was genuinely transformative for Impel, with the licensing and timely release of Trudhesa. Since their commercial release in early October, they’ve been ecstatic with the early uptake and prescription trends they’ve seen in the market. They are convinced that Impel’s improved balance sheet will give them the funds they need to maintain the successful commercialization of Trudhesa given the recent follow-on equity offering. It will also aid in the development of INP105 for the cure of agitation and violence in people with autism.

Latest

5 Best NFTs Stocks to Buy In 2022

It is no secret that investors are looking to...

The Kraft Heinz Company (KHC) Earnings Preview: What to Expect From Earnings

The Kraft Heinz Company (NASDAQ: KHC) intends to submit...

Citigroup Upgraded Nokia Oyj (NOK) To Buy with Price Target of $6.8

Nokia Oyj (NYSE: NOK), a communications equipment developer, is...

The Chart for Block Inc. (SQ) Stock Is Flashing Mixed Signals

In the first quarter, large investment funds expanded their...

Newsletter

 

Don't miss

Beating Analyst Forecasts and Coming Out on Top: Confluent Inc. (CFLT)

Confluent Inc. (NASDAQ: CFLT) reported its second-quarter earnings last...

Qualcomm Incorporated (QCOM): Analyst Viewpoints To Future Growth

In trading on July 14, shares of chipmaker Qualcomm...

Chevron Corporation (CVX) provides details about its hydrogen future

The huge hydrogen investment plan of the oil and...

Healthy Upside Potential: Maxar Technologies Ltd. (MAXR)

In May 25 trading, shares of space business Maxar...

Atkore Inc. (ATKR) stock: Better Than You Think

Atkore Inc. (NYSE:ATKR), a manufacturer of infrastructure, electrical, and...

No matter how cynical the overall market is Plains GP Holdings L.P. (PAGP) performance over the last week is recorded 0.27%

Plains GP Holdings L.P. (NASDAQ: PAGP) on August 05, 2022, started off the session at the price of $10.96, soaring 0.18% from the previous...

$17.26M in average volume shows that Pinterest Inc. (PINS) is heading in the right direction

August 05, 2022, Pinterest Inc. (NYSE: PINS) trading session started at the price of $22.41, that was 0.09% jump from the session before. During...

$5.85M in average volume shows that Arrival (ARVL) is heading in the right direction

On August 05, 2022, Arrival (NASDAQ: ARVL) opened at $1.66, lower -4.05% from the last session. During the day, the shares moved up to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here


134699

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

129712

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam

DOWNLOAD FREE EBOOK

BEST GROWTH STOCKS 2022

We put together a list of the best stocks that we

think can explode over the next 12 months.

134709

SPECIAL GIFT

134710
134711
134712

  What you will Get ?

   Best Growth

   Stocks eBook

        Hot Stocks Alert

     before the opening

                  bell

        Special Offer

      and reports from 

        our partners

134713

100% free. stop anytime no spam

GET YOUR FREE COPY NOW

134702

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

DOWNLOAD FREE EBOOK

BEST INFLATION STOCKS 2022

We put together a list of the best stocks that

we think can explode over the next 12 months.

134703

SPECIAL GIFT

134704
134705
134706

  What you will Get ?

   Best Inflation

   Stocks eBook

        Hot Stocks Alert

     before the opening

                  bell

        Special Offer

      and reports from 

        our partners

100% free. stop anytime no spam

GET YOUR FREE COPY NOW